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Objectives:Rapid, cost-effective and objective methods for antimicrobial susceptibility testing ofNeisseria gonorrhoeae
would greatly enhance surveillance of antimicrobial resistance. Etest, disc diffusion and agar dilution methods are sub-
jective, mostly laborious for large-scale testing and take 24 h. We aimed to develop a rapid broth microdilution
assay using resazurin (blue), which is converted into resorufin (pink fluorescence) in the presence of viable bacteria.
Methods: The resazurin-based broth microdilution assay was established using 132 N. gonorrhoeae strains and
the antimicrobials ceftriaxone, cefixime, azithromycin, spectinomycin, ciprofloxacin, tetracycline and penicillin.
A regression model was used to estimate the MICs. Assay results were obtained in7.5 h.
Results: The EC50 of the dose–response curves correlated well with Etest MIC values (Pearson’s r"0.93). Minor errors
resulting from misclassifications of intermediate strains were found for 9% of the samples. Major errors (susceptible
strains misclassified as resistant) occurred for ceftriaxone (4.6%), cefixime (3.3%), azithromycin (0.6%) and tetracyc-
line (0.2%). Only one very major error was found (a ceftriaxone-resistant strain misclassified as susceptible). Overall
the sensitivity of the assay was 97.1% (95% CI 95.2–98.4) and the specificity 78.5% (95% CI 74.5–82.9).
Conclusions: A rapid, objective, high-throughput, quantitative and cost-effective broth microdilution assay was
established for gonococci. For use in routine diagnostics without confirmatory testing, the specificity might re-
main suboptimal for ceftriaxone and cefixime. However, the assay is an effective low-cost method to evaluate
novel antimicrobials and for high-throughput screening, and expands the currently available methodologies for
surveillance of antimicrobial resistance in gonococci.
Introduction
Neisseria gonorrhoeae is a very fastidious bacterium that causes
the sexually transmitted infection gonorrhoea. Gonorrhoea is a
public health concern globally1,2 and N. gonorrhoeae has de-
veloped resistance to all antimicrobials introduced for treatment.3
Accordingly, enhanced surveillance of antimicrobial susceptibility
in N. gonorrhoeae is imperative globally.1 Ideally, this surveillance
should be performed using methods determining the MICs of rele-
vant antimicrobials. MIC-based methods are also valuable to dir-
ectly inform treatment after laboratory results are available and
evaluate in vitro efficacy of novel antimicrobials.
Owing to the lack of any appropriate broth medium for MIC de-
termination, MIC-based susceptibility testing of N. gonorrhoeae has
been limited to disc diffusion, Etest and the agar dilution method
(gold standard). Essential agreement with the agar dilution method
is defined as +1 doubling dilution and should ideally be .90% for
diagnostic purposes where the same resistance breakpoints are
applied.4 Etest has shown excellent agreement with the agar dilu-
tion method in many settings.4–7 However, discordant results have
been found, particularly when different growth media were used.8
A multicentre international study revealed that the categorical
agreement between Etest and agar dilution was 88%, but was
very poor for disc diffusion.9 Unfortunately, all these methods are
relatively slow (24 h), subjective, require expertise and/or are ex-
pensive. Faster methods that allow results to be obtained on the
same day have been developed in the past for other bacteria,10,11
but are not available forN. gonorrhoeae.
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For many bacterial species, broth microdilution is the reference
method due to accuracy, low costs and high versatility.12,13
Several attempts have been made to develop a broth microdilu-
tion method also for N. gonorrhoeae, but none of these has been
particularly accurate and suitable for routine use.14–16 It is difficult
to synchronize the growth of different N. gonorrhoeae strains and
effects such as autolysis occur when the bacteria enter the station-
ary phase.17–19 Chemically defined Graver–Wade (GW) broth20
supports the growth of phylogenetically diverse auxotypes and
clinical isolates, and might be a suitable medium for susceptibility
testing.21,22
Unfortunately, MIC values based on doubling dilution series
are left-, interval- or right-censored discrete data, which makes
error statistics challenging.23 The potency of drugs in pharma-
cology is frequently measured with dose–response curves (Hill
models), as this allows the estimation of the effective concen-
tration (EC) at a specified response level.24 Furthermore, EC val-
ues on a continuous scale take the variability of the data into
account by calculating CIs. In the field of toxicology the lower CI
is defined as the non-toxic concentration. This so-called bench-
mark dose approach has largely replaced methods that rely on
dense dose spacing because of its statistical superiority and re-
duction of animal use.25–28 Furthermore, the shape of the dose–
response curve can provide additional valuable information on
the compounds being tested.24 The Hill coefficient can provide
information about the pharmacodynamic properties of an anti-
microbial and has been used in modelling studies of single and
dual antimicrobial effects.21,22,29–31 However, the interpretation
and significance of the Hill coefficient has been unclear in previ-
ous studies and laborious colony counting has limited these
studies to a few strains.
The biological response to a compound can be measured using
different readouts. Traditionally the MIC is defined as the concen-
tration of an antimicrobial that inhibits visual growth, but methods
to quantify the number of bacterial cells more objectively are avail-
able. Methods in which OD (at e.g. OD600 or OD450), resazurin
(Alamar blue), MTT, luciferase (ATP levels) and lactate dehydro-
genase are measured are widespread, with readouts that correl-
ate with the number of cells.32 Resazurin is a blue dye that is
converted into pink-fluorescent resorufin in the presence of meta-
bolically active cells.33,34 Unlike OD, a measure of growth inhibition,
it reflects the viability of cells and is potentially suitable for time–kill
assays. Resazurin has an excellent signal-to-noise ratio and has
been used previously in screening for toxicity testing,35 high-
throughput applications,36 biofilm screening37 and MIC test-
ing.33,38–40
The aim of this study was to develop a resazurin-based broth
microdilution assay for antimicrobial susceptibility testing of
N. gonorrhoeae that is rapid, objective, scalable, quantitative and
inexpensive. Three datasets were generated in this study. The
2008 WHO N. gonorrhoeae reference strains (n"8)41,42 were
studied to ensure the reproducibility of the assay and to compare
multiple measurement endpoints between 0 and 15 h. Training
data consisting of 84 N. gonorrhoeae strains were used to develop
a regression model for estimating the MIC from dose–response
curves. Finally, a panel of 40 strains with blinded MICs was used for
validation.
Materials and methods
Bacterial strains, culture and broth microdilution assay
The variability and reproducibility of the assay were validated in eight WHO
reference strains (three replicates).41,42 Additionally, 84 gonococcal strains
were used as training data to develop a regression model for estimating
the MIC after 6 h of incubation time (one replicate). The assay was finally
validated with 40 gonococcal strains with blinded MICs (one replicate). The
blinded strains were selected to represent a wide variety of antibiograms.
The strains were preserved in glycerol stocks at#80C. All strains were sub-
sequently cultured on Chocolate Agar PolyViteX (bioMe´rieux, Marcy-l’Etoile,
France) at 37C in a humid 5% CO2-enriched atmosphere for 16–18 h and
then sub-cultured once for 16 h. A McFarland standard of 0.5 was prepared
for each strain and 1 mL of bacterial suspension was further diluted to
1%107 cfu/mL in 15 mL of heated (37C) GW broth.20 A volume of 90mL of
this suspension was added to 96-well round-bottom microtitre plates
(360mL wells), with each well containing 10mL of a previously prepared dilu-
tion series. Dilution series of the antimicrobials were prepared in GW me-
dium. Positive control (GW medium containing 1% Triton X-100) and
negative control (10mL of GW medium) were added to the first and last
well, respectively. The plates were incubated for 6 h at 37C in a humid 5%
CO2-enriched atmosphere. Detailed standard operating procedures, includ-
ing Figure S1, are available as Supplementary data at JACOnline.
Resazurin readouts
Resazurin powder (Sigma–Aldrich, China) was diluted in PBS (pH 7.4) to a
final concentration of 0.1 mg/mL. We ensured that the pH of the highest
antimicrobial concentration was neutral in all samples to avoid artefacts.
After incubation of the broth microdilution plates, 50mL of the dye was
added to each well and mixed using an electronic multichannel dispenser.
The plates were incubated for 75 min at 37C. Fluorescence was then
measured at 560 and 590 nm excitation in a plate reader (Varioskan Flash,
Thermo Scientific).
Etest MIC
The Etest MICs (bioMe´rieux) were determined in accordance with the
manufacturer’s instructions, on gonococcal resistance agar plates (GCRAPs)
[3.6% Difco GC Medium Base agar (BD Diagnostics, Sparks, MD, USA) supple-
mented with 1% haemoglobin (BD Diagnostics) and 1% IsoVitalex (BD
Diagnostics)].
Dose–response modelling
The antimicrobial effect on the different bacterial strains was quantified
with dose–response curves. We first subtracted the background fluores-
cence resulting from dead bacteria in the positive control wells from the
resazurin readout. We then fitted a sigmoidal dose–response curve to the
fluorescence data of each antimicrobial–strain combination:43,44
f xð Þ ¼ uþ l u
1þ eHðx–ln EC50ð ÞÞ (1)
where f(x) is the fluorescence, x is the natural logarithm of the antibiotic
concentration, and u and l describe the upper and lower asymptote, re-
spectively. The EC50 is the antibiotic concentration at which the effect is
half-maximal andH denotes the slope of the sigmoidal function, i.e. the Hill
coefficient. Next, the data were divided by u to normalize all dose–response
curves to 100% viability. Hill coefficient differences across antimicrobials
were tested with pairwise t-tests. Hierarchical complete linkage clustering
was used to compare antimicrobial similarity.45
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Samples were considered to be above the limit of detection, and there-
fore categorized as resistant, if the antibiotic, at its highest concentration,
reduced viability by,50%. This was the case for six samples in the training
data (n"588) and nine samples in the validation data (n"280). Excluding
samples that were above or below the limit of detection (including Etest
MICs beyond the limit of detection) resulted in 571 evaluable samples in
the training data and 266 samples in the validation data. Reference strain
data were not included to avoid bias from replicate testing of these sam-
ples. The relationship between EC50 and Etest was analysed for the training
data by log-transforming both values and fitting a linear regression:
lnðEtestÞ ¼ aþ b lnðEC50Þ þ e (2)
where e is a normally distributed error. The slope and intercept of this re-
gression were then used to predict the MIC from the EC50 values for the
blinded strains. 95% CIs for each predicted MIC were calculated using 105
bootstrap samples taking into account the uncertainty from the sigmoidal
model and the linear regression model. The analysis pipeline, descriptive
statistics and raw data are available from GitHub (https://github.com/sunni
vas/ResazurinMIC).
Essential agreement with Etest
Essential agreement was defined as the percentage of strains with pre-
dicted MICs that did not deviate by more than +1 doubling dilution from
Etest MICs. Deviations from the Etest MICs were calculated as log2 differ-
ences from the predicted MIC (837 evaluable samples for training and val-
idation data). Reference strain data were not included to avoid bias from
replicate testing of these samples.
Categorical agreement with Etest
The strains were categorized as susceptible (S), intermediate (I) or resistant
(R) to each antimicrobial in accordance with the EUCAST 2016 guidelines.46
As previously described,47 minor errors were defined as misclassifications
of intermediate strains as susceptible or resistant. Major errors were sus-
ceptible strains misclassified as resistant. Very major errors were resistant
strains that were misclassified as susceptible. The EC50 values are read on a
continuous scale and therefore nearly identical values around a resistance
breakpoint (e.g. 0.125 and 0.126) can result in categorical errors. Sensitivity
and specificity of the assay were calculated as previously described48 for
the resistant strains (true positive samples), intermediate strains (true posi-
tive samples) and susceptible strains (true negative samples).
Results
Dose–response modelling
The 2008 WHO reference strains (n"8) were exposed to ceftriax-
one, cefixime, azithromycin, spectinomycin, ciprofloxacin, tetra-
cycline or penicillin for a time course from 0–15 h (Figure S2). After
6 h, the difference between dead and viable gonococcal cells was
sufficiently pronounced to fit dose–response curves to the data.
For this endpoint of 6 h, the coefficient of variation (CV) was calcu-
lated for the EC50 of three independent experiments. The CV
ranged from 1.7% to 87% and the intra-assay CV was 29%
(n"56) (Figure S3). Dose–response curves were gradually shifted
towards higher concentrations, indicating decreased potency of
the antimicrobials against the intermediate and resistant strains
compared with susceptible strains (Figure 1). There was a clear
separation of susceptible and resistant strains for ciprofloxacin and
spectinomycin. For the b-lactam antimicrobials ceftriaxone, cefix-
ime and penicillin the Hill coefficients (slopes) were more
heterogeneous than for the other samples (Figure 1). The mean
(+SD) of this parameter gradually increased from ceftriaxone
(1.6+1.3) to cefixime (1.9+1.5), tetracycline (2.1+0.9), penicillin
(2.5+1.7), azithromycin (2.6+1.5), ciprofloxacin (2.7+1.2) and
spectinomycin (2.9+1.7). A pairwise t-test showed that the differ-
ences between the antimicrobials were significant (P,0.005)
when the distance between the means was .0.5 (Figure S4a).
Furthermore, hierarchical clustering showed a high similarity of
the Hill coefficient for the b-lactam antimicrobials ceftriaxone, cef-
ixime and penicillin compared with the other antimicrobials (Figure
S4b).
For the training data (84 strains), Pearson’s correlation between
the Etest MICs and EC50 values of all antimicrobials was
0.93 (Figure 2a). Compared with the Etest values, the EC50
values were systematically lower, with a median deviation of
#1.68 doubling dilutions (Figure 2b). The regression parameters
a (a^ ¼ 1:10; SDa^ ¼ 0:048) andb (b^ ¼ 1:00; SDb^ ¼ 0:016) of the lin-
ear log–log regression were used to predict the 837 MICs of the
training and validation data. The deviation of the predicted MIC
from Etest followed a normal distribution with a median of#0.015
and 95% of the deviations ranged between #4.45 and 9.22.
Outliers were mostly attributed to the b-lactam antimicrobials
penicillin (e.g. overestimation in b-lactamase-producing strains)
and cefixime and ceftriaxone (e.g. potentially biphasic or triphasic
curves with large CIs). One example of a strain with biphasic curves
for ceftriaxone and cefixime was studied in detail (Figure S5).49 The
75% quartiles for the deviations were larger for azithromycin, cef-
ixime and ceftriaxone compared with ciprofloxacin, penicillin,
spectinomycin and tetracycline (Figure 2c). The essential agree-
ment between the Etest MICs and the predicted MICs was 53% for
all antimicrobials, being lowest for cefixime (31%) and highest for
penicillin (61%).
Categorical agreement
The Etest and predicted MICs (n"868) were classified as suscep-
tible, intermediate resistant and resistant according to the EUCAST
2016 resistance breakpoints46 (Figure 3). The sensitivity of the
assay was 97.1% (95% CI 95.2–98.4). Minor errors resulting from
misclassifications of intermediate resistant strains were found
for 9% of the data. For penicillin, spectinomycin and ciprofloxacin
no major errors were identified. False-positive misclassifications
(S misclassified as R), i.e. major errors, occurred for tetracycline
(0.2%), azithromycin (0.6%), cefixime (3.3%) and ceftriaxone
(4.6%) for a total of 9% of the data. One very major error (R mis-
classified as S) occurred for ceftriaxone (Etest MIC 0.19 versus
0.053 mg/L). Many predicted MIC values (16.5%) had 95% CIs
spanning two categories. The overall specificity of the assay was
78.5% (95% CI 74.5–82.9).
Discussion
The developed resazurin-based broth microdilution assay was able
to discriminate between resistant and susceptible strains relatively
reliably, was faster (7.5 h for results) than currently available MIC
methods for N. gonorrhoeae and had an excellent sensitivity of
97.1% (95% CI 95.2–98.4). The gold standard MIC-based method
agar dilution and the Etest method are both based on subjective,
visual readouts and are therefore limited to a relatively low
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throughput. Dose–response modelling allows the precise estima-
tion of the EC50 of antimicrobials from a continuous scale and pro-
vides CIs rather than having the precision limited by doubling
dilutions. It is inherently difficult to apply resistance breakpoints
that were designed for doubling dilution-based methods to dose–
response curve-based MICs. This was reflected by many categor-
ical errors resulting from estimates that had CIs overlapping two S/
I/R categories. The performance of the assay was excellent for
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Figure 1. Potency shift of antimicrobials across different strains of N. gonorrhoeae. Dose–response curves for all strains and antimicrobials are shown
(except samples above the limit of detection). Strains that were classified as susceptible according to EUCAST 2016 MIC breakpoints46 are coloured
green, intermediate strains blue and resistant strains red. The gradual shift of the potencies (EC50) towards higher concentrations can be observed for
all antimicrobials.
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ciprofloxacin, penicillin and spectinomycin (no major errors) and
acceptable for azithromycin (0.6% major errors) and tetracycline
(0.2% major errors).
The deviations of resazurin-based MICs from Etest MICs fol-
lowed a normal distribution. Outliers were mainly attributed to the
b-lactam antimicrobials and contributed to the suboptimal
essential agreement and assay specificity of only 78.5% (95% CI
74.5–82.9). For penicillin, substantially higher MICs were measured
with the resazurin assay, e.g. for b-lactamase-producing strains.
For cefixime and ceftriaxone there were many false-positive re-
sults and consequently an overestimation of resistance was meas-
ured. The complex mechanism of action and evolution of
resistance to these antimicrobials is not fully understood and in-
volves several resistance determinants in multifaceted inter-
actions (penA, penB, mtrR, factor X).3,50 The correlation of EC50 and
MIC has been previously shown to be not strictly linear and was
largely influenced by different PBPs in Streptococcus pneumo-
niae.51 The binding kinetics of a mechanism involving several tar-
gets and/or resistance determinants can result in dose–response
curves that are biphasic and potentially triphasic (Figure S5).22,49
In these cases the correlation between EC50 and Etest MIC differs
from those in dose–response curves with only one inflection point
and can result in false-positive results.
Performing the regression analysis for the different antimicro-
bials separately might improve the assay specificity, particularly
for the b-lactam antimicrobials. An endpoint of 6 h provided only a
snapshot of the antimicrobial properties and examining many
more timepoints, more starting inocula and a very large number of
strains, covering a wide range of MICs and ideally including in vitro-
selected resistant strains, might also provide valuable data for
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Figure 2. Correlation and deviations between Etest MICs and predicted MICs. (a) Linear regression between EC50 and Etest MIC for the training data
(n"571). Pearson’s correlation coefficient for the linear regression (blue line) was 0.93. Slope and intercept for a perfect correlation are drawn as a
dashed black line for comparison. (b) The kernel density function of the EC50 values for the training data (n"571) is shown in pink (median #1.68).
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improvements. Scaling up the assay to a robotic platform might be
necessary for appropriate examination of all these parameters
and strains.
Despite these limitations, the developed rapid resazurin-
based broth microdilution assay was highly objective (avoiding
visual subjective readout) and employs a standardized algo-
rithm reducing operator bias, which can be especially valuable
in multicentre studies. These properties, and the low price of
resazurin, are especially valuable when screening large libraries
of new compounds, antimicrobials or antimicrobial combin-
ations. Frequently, the question that needs to be answered is
the potency of antimicrobials relative to each other rather than
absolute numbers. The b-lactam antimicrobials cefixime, cef-
triaxone and penicillin displayed significantly lower Hill coeffi-
cients than the other antimicrobials. Information about this
parameter is useful for research questions beyond susceptibility
testing, such as combination therapy and pharmacodynamic
modelling.
In summary, the developed resazurin-based broth microdilu-
tion assay is a rapid, objective, high-throughput, quantitative
and cost-effective new tool for studying N. gonorrhoeae in liquid
culture. The Hill coefficient could be compared for a large
number of strains, highlighting differences between antimicro-
bials. The new assay opens up avenues for high-throughput syn-
ergy testing, evaluation of novel antimicrobials and surveillance
of resistance.
Funding
This study was funded through an Interdisciplinary PhD (IPhD) project from
SystemsX.ch (The Swiss Initiative for Systems Biology), RaDAR-Go (RApid
Diagnosis of Antibiotic Resistance in Gonorrhoea; funded by the Swiss
Platform for Translational Medicine), and the €Orebro County Council
Research Committee and the Foundation for Medical Research at €Orebro
University Hospital, Sweden.
Transparency declarations
None to declare.
Supplementary data
The standard operating procedures and Figures S1–S5 are available as
Supplementary data at JACOnline.
n= 4
n= 0
n= 0
n= 1
n= 30
n= 6
n= 0
n= 7
n= 76
S (n= 4) I (n= 37) R (n= 83)
S 
(n
=
5)
I 
(n
=
37
)
R 
(n
=
82
)
Penicillin
n= 117
n= 0
n= 0
n= 7
S (n= 117) R (n= 7)
S 
(n
=
11
7)
R 
(n
=
7)
Spectinomycin
n= 0
n= 1
n= 0
n= 1
n= 3
n= 0
n= 2
n= 21
n= 96
S (n= 1) I (n= 4) R (n= 119)
S 
(n
=
3)
I 
(n
=
25
)
R 
(n
=
96
)
0.1 101000 0.1 101000 0.1 101000 1 100 10 000 1 100 10 000 1 100 1 100 1 100
Tetracycline
Model classification
EU
CA
ST
 c
la
ss
ifi
ca
tio
n
n= 16
n= 12
n= 0
n= 5
n = 9
n= 6
n= 5
n = 17
n= 54
S (n= 28) I (n= 20) R (n= 76)
I 
(n
=
38
)
R 
(n
=
60
)
Azithromycin
n= 36
n= 0
n= 0
n= 1
n = 0
n= 0
n= 0
n= 0
n= 87
S (n= 36) I (n= 1) R (n= 87)
S 
(n
=
37
)
I 
(n
=
0)
R 
(n
=
87
)
Ciprofloxacin
n= 74
n= 1
n= 40
n= 9
S (n= 75) R (n= 49)
S 
(n
=
11
4)
R 
(n
=
10
)
Ceftriaxone
n= 60
n= 0
n= 29
n= 35
S (n= 60) R (n= 64)
S 
(n
=
89
)
R 
(n
=
35
)
0.1 10 1000 0.1 10 1000 0.1 10 1000 0.01 1 100 0.01 1 100 0.01 1 100 0.001 0.1 10 1000 0.001 0.1 10 1000 0.001 0.1 10 0.001 0.1 10
Cefixime
S 
(n
=
26
)
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